http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008100933-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be79f9adad5a024cc5afa9d5361a3cea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3c7e0a96dc1d3d2c16f7ba909eb9b394
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9c004af0122aff8a55f96d2e53889f96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61fba7cbdb0abe27e49e4bb3381d2194
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N33-02
filingDate 2008-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dd155a9e0db3dad17e65758d9919c2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8777f9e14225553f008875bfee51db03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_406c0732f437a342b141a33ccafb9df7
publicationDate 2008-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2008100933-A3
titleOfInvention Reducing side effects of tramadol
abstract The invention provides methods of reducing the side effects of tramadol. Accordingly, in one embodiment, the invention provides a method of reducing the incidence of newly-discovered side effects related to sexual function in human males taking a tramadol material. The method comprises administering a phosphodiesterase inhibitor to a male taking the tramadol material. The invention also provides pharmaceutical compositions. In one embodiment, the composition comprises a tramadol material and a phosphodiesterase inhibitor. The invention further provides kits. In one embodiment, the kit comprises a tramadol material and a phosphodiesterase inhibitor.
priorityDate 2007-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6974839-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005054688-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003031712-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004087591-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0960621-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533818
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398848
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID33741

Total number of triples: 35.